Thrilled to share that the DESTINATION 2 trial has received the green light for recruitment at The Christie! Looking forward to welcoming patients and making meaningful progress together #clinicaltrials #thechristie #oncologyresearch #prostatecancer

Congratulations to our very own Liz Miles, incredible colleague, mentor & friend on her #ESTRO25 Interdisciplinary Award. A true champion for #collaboration and #RTQA. So well deserved- we could not be prouder!

Regional LN delineation variability in #BrCa RT within the Fast Forward trial. Despite this variability, all mandatory constraints were adhered to. #RTQA plays a central role in providing support & guidance to participating centres www.sciencedirect.com/science/arti...

We are thrilled to announce opening of the ANDROMEDA study! This represents another significant achievement stemming from MOMENTUM infrastructure. We’re excited to leverage our advanced Unity MR-Linac capabilities to deliver dose-escalated adaptive radiotherapy for patients with rectal cancer.

Happy to announce that the 7000th participant for MOMENTUM has been enrolled at UMC Utrecht yesterday!

For muscle-invasive bladder cancer, the Lancet Oncology paper by Zlotta et al is the best comparative effectiveness study of TMT versus RC. How can we use this study to communicate the risks of delayed cystectomy to patients? Peppin A et al provide an answer at GU ASCO 2025:

#GU25 #OncSky #MedSky

www.phiro.science/article/S240... Another elegant demonstration of how simplifying complex workflows yields powerful results. By leveraging MOMENTUM's infrastructure, this team shows streamlined adaptive radiotherapy maintains quality while reducing treatment times. Congratulations!